Deborah Dunsire, M.D., was named by EnVivo Pharmaceuticals as its new president and chief executive officer. In line with her promotion, she joined the company's board of directors.
Dr. Dunsire previously held the same positions on Millennium: The Takeda Oncology Company. She has been in the industry for over 25 years, heading several transactions related to scientific, operational, clinical, and commercial businesses.
Her work in Millennium was recognized by the company. During her leadership, she focused on the research and development sector, transforming the company into a leading name in the biotechnology industry. Due to this, the company (previously Millennium Pharmaceuticals) was bought by Taked Pharmaceutical for US$8.8 billion. The buyout is considered to be the biggest acquisition in the biotech industry.
"Deborah's ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled," commented Dr. Stephen Knight, chairman of EnVivo's board.
Join the Conversation